E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar, V., Law, D.A., Ibsen, E., Breinberg, D., Cass, K.M., DuBridge, R.B., Evangelista, F., Henshall, S.M., Hevezi, P., Miller, J.C., Pong, M., Powers, R., Senter, P., Stockett, D., Sutherland, R.L., von Freeden-Jeffry, U., Willhite, D., Murray, R., Afar, D.E., Ramakrishnan, V.
Notes: Plated at a density of 2500 cells/well in 96-well plates and allowed to recover overnight, the cells were then challenged for 1 hour with E-selectin monoclonal antibody or antibody drug conjugate, washed and allowed to proliferate in fresh growth media for four days. Cell viability was assessed using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay. (3152)
Expand Full Notes »